. . . "To further examine whether the inclusion of all studies was biasing the results, the analysis was repeated with the study with lowest AMI risk [18], and there was no difference in overall risk.Another potential concern is that some of the studies relied on pharmaceutical company sponsorship and thus need to be interpreted with caution; this is particularly relevant in relation to naproxen." .